Targeted alpha anticancer therapies: update and future prospects

References

• KöhlerGMilsteinCContinuous cultures of fused cells secreting antibody of predefined specificityNature197525655174954971172191
   PubMed Web of Science ®Google Scholar
• GoldenbergDMTargeted therapy of cancer with radiolabeled antibodiesJ. Nucl Med200243569371311994535
   PubMed Web of Science ®Google Scholar
• BronsSJakobBTaucher-ScholzGKraftGHeavy ion production of single- and double-strand breaks in plasmid DNA in aqueous solution2001Phys Med17Suppl 121721811776277
   PubMed Web of Science ®Google Scholar
• KerrJFA histochemical study of hypertrophy and ischaemic injury of rat liver with special reference to changes in lysosomesJ Pathol Bacteriol19659024194355849603
   PubMedGoogle Scholar
• ElgqvistJTargeted Alpha TherapyCurrent Radiopharmaceuticals20114317622201706
   PubMedGoogle Scholar
• SgourosGRadioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdleJ Nucl Med19953610191019127562063
   PubMed Web of Science ®Google Scholar
• JurcicGJLarsonSMSgourosGTargeted αparticle immunotherapy for myeloid leukemiaBlood200210041233123912149203
   PubMed Web of Science ®Google Scholar
• AllenBJRajaCRizviSSongEYGrahamPTumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancerPhys Med Biol20075213L15L1917664565
   PubMed Web of Science ®Google Scholar
• RajaCGrahamPRizviSMInterim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanomaCancer Biol Ther20076684685217495524
   PubMed Web of Science ®Google Scholar
• ChangSSReuterVEHestonWDBanderNHGrauerLSGaudinPBFive different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculatureCancer Res199959133192319810397265
   PubMed Web of Science ®Google Scholar
• Pandit-TaskarNLasonSMCarrasquilloJABone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichlorideJ Nucl Med201455226827424343987
   PubMed Web of Science ®Google Scholar
• MartinVMSiewertCScharlAImmunomagnetic enrichment of disseminated epithelial tumour cells from peripheral blood by MACsExp Hematol19982632522649502622
   PubMed Web of Science ®Google Scholar
• WangJAbbas RizviSMMadiganMCControl of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha immunoconjugatesProstate200666161753176716955401
   PubMed Web of Science ®Google Scholar
• SongYJQuCFRizviSMACytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clustersCancer Lett2006234217618315961220
   PubMed Web of Science ®Google Scholar
• AllenBJRajaCRizviSIntralesional targeted alpha therapy for metastatic melanomaCancer Biol Ther20054121318132416322682
   PubMed Web of Science ®Google Scholar
• AzzamEILittleJBThe radiation-induced bystander effect: evidence and significanceHum Exp Toxicol2004232616515070061
   PubMed Web of Science ®Google Scholar
• AllenBJInternal high linear energy transfer (LET) targeted radiotherapy for cancerPhys Med Biol20065113R327R34116790911
   PubMed Web of Science ®Google Scholar
• SongEYRizviSMAQuCFPharmacokinetics and toxicity of 213Bi-labelled PAI2 in preclinical targeted alpha therapy for cancerCancer Biol Therapy200766898904
   PubMed Web of Science ®Google Scholar
• DahleJJonasdottirTJHeyerdahlHAssessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximabEur J Nucl Med Mol Imaging20103719310219593562
   PubMed Web of Science ®Google Scholar
• HuangCYObornBMGuatelliSAllenBJMonte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapyMed Phys20123931282128822380360
   PubMed Web of Science ®Google Scholar
• SeidlCZöcklerCBeckRQuintanilla-MartinezLBruchertseiferFR177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213BiEur J Nucl Med Mol Imaging201138231232221072513
   PubMed Web of Science ®Google Scholar
• WildDFrischnknectMZhangHAlpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)Cancer Res20117131009101821245097
   PubMed Web of Science ®Google Scholar
• SongEYRizviSMQuCFThe cytokinesis–block micronucleus assay as a biological dosimeter for targeted alpha therapyPhys Med Biol200853231932818184988
   PubMed Web of Science ®Google Scholar
• HuangCYGuatelliSObornBAllenBJBackground dose for systemic targeted alpha therapyProg Nucl Sci Tech20112187190
   Google Scholar
• SgourosGRoeskeJCMcDevittMRMIRD Pamphlet No 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapyJ Nucl Med201051231132820080889
   PubMed Web of Science ®Google Scholar
• AllenBJSoTRizviSMASongEYFernandezHRLutz-MannLMutagenesis induced by targeted alpha therapy using 213Bi-cDTPA-9.2.27 in lacZ transgenic miceCancer Biol Therapy200989777781
   PubMed Web of Science ®Google Scholar
• AllenBJCan alpha-immunotherapy succeed where other systemic modalities have failed?Nucl Med Commun199920320520710093068
   PubMed Web of Science ®Google Scholar
• AllenBJClinical trials of targeted alpha therapy for cancerRev Recent Clin Trials20083318519118782076
   PubMedGoogle Scholar
• McDevittMRMaDLaiLTTumor therapy with targeted atomic nanogeneratorsScience200129455461537154011711678
   PubMed Web of Science ®Google Scholar
• FinnRDMcDevittMRScheinbergDARefinements and improvements for Bi-213 production and use as a targeted therapeutic radiopharmaceuticalJ Labelled Compds Radiopharm199740293
   Google Scholar
• Abbas RizviSMSarkarSGoozeeGAllenBJRadioimmunoconjugates for targeted alpha therapy of malignant melanomaMelanoma Res200010328128910890383
   PubMed Web of Science ®Google Scholar
• AllenBJRizviSMTianZPreclinical targeted alpha therapy for subcutaneous melanomaMelanoma Res200111217518211333128
   PubMed Web of Science ®Google Scholar
• Abbas RizviSMAHennikerAJGoozeeGAllenBJIn vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopesLeuk Res2002261374311734302
   PubMed Web of Science ®Google Scholar
• RizviSMAllenBJTianZGoozeeGSarkarSIn vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancerColorectal Dis20013534535312790958
   PubMedGoogle Scholar
• LiYRizviSMRansonMAllenBJ213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal modelBr J Cancer20028671197120311953871
   PubMed Web of Science ®Google Scholar
• LiYRizviSMABrownJAntigenic expression of human prostate cancer cell lines for in vitro multiple-targeted a-therapy with 213Bi-conjugatesInt J Radiat Oncol Biol Phys200460389690815465208
   PubMed Web of Science ®Google Scholar
• LiYCozziPJQuCFCytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugateCancer Letters2004205216117115036648
   PubMed Web of Science ®Google Scholar
• KneifelSCordierDGoodSLocal targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance pClin Cancer Res200612123843385016778112
   PubMed Web of Science ®Google Scholar
• ParkSIShenoiJPagelJMConventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual diseaseBlood2010116204231423920702781
   PubMed Web of Science ®Google Scholar
• QuCFSongEYLiYMUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugateBrit J Cancer2004912086209315599383
   PubMed Web of Science ®Google Scholar
• QuCFSongEYLiYPre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic CancerClin Exp Metastasis200522757558616475028
   PubMed Web of Science ®Google Scholar
• AllenBJRizviSMQuCFSmithRCTargeted alpha therapy approach to the management of pancreatic cancerCancers (Basel)2011321821184324212784
   PubMedGoogle Scholar
• QuCFSongYJLiYIn Vivo and In Vitro Inhibition of Pancreatic Cancer Growth by Targeted Alpha Therapy using 213Bi-CHX.A”-C595Cancer Biol Therapy200548e31e36
   Web of Science ®Google Scholar
• AnderssonHCederkrantzEBäckTIntraperitoneal alpha-particle radioimmunotheapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab’)2 – a phase 1 studyJ Nucl Med20095071153116019525452
   PubMed Web of Science ®Google Scholar
• RizviSAllenBLeeCOrthotopic administration of (213) Bi-bevacizumab inhibits progression of PC3 xenografts in the prostateImmunotherapy20124554955422642336
   PubMed Web of Science ®Google Scholar
• SongEYQuCFRizviSMBismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites modelCancer Biol Ther200871768018347423
   PubMed Web of Science ®Google Scholar
• QuCFLiYSongYJMUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugateBr J Cancer200491122086209315599383
   PubMed Web of Science ®Google Scholar
• QuCFSongYJLiYRizviSMIn vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A”-C595Cancer Biol Ther20054884885316082185
   PubMed Web of Science ®Google Scholar
• AllenBJTianZRizviSMLiYRansonMPreclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2Brit J Cancer200388694495012644835
   PubMed Web of Science ®Google Scholar
• LiYTianZRizviSMBanderNHAllenBJIn vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigenProstate Cancer and Prostatic Dis2002513646
   PubMed Web of Science ®Google Scholar
• TagawaSTMilowskyMIMorrisMPhase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerClin Cancer Res201319185182519123714732
   PubMed Web of Science ®Google Scholar
• JurcicJRosenblatTLMcDevittMRAlpha-particle immunotherapy for acute myeloid leukemia with Bismuth-213 and actinium-225Presented at: 7th Symposium on targeted Alpha TherapyJuly 17–19, 2011Berlin
   Google Scholar
• AllenBJRajaCRizviSMAGrahamPKearsleyJHNew Directions for Clinical Trials of Targeted Alpha Therapy for Metastatic MelanomaCurrent Radiopharmaceuticals200813240250
   Google Scholar
• AllenBJSinglaAARizviSMAnalysis of patient survival in a Phase 1 trial of systemic targeted α-therapy for metastatic melanomaImmmunotherapy20113910411050
   PubMed Web of Science ®Google Scholar
• ZalutskyMRReardonDAAkabaniGClinical experience with the alpha-particle emitting 211At: treatment of recurrent brain tumours patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6J Nucl Med2008491303818077533
   PubMed Web of Science ®Google Scholar
• CordierDForrerFBruchertseiferFTargeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trialEur J Nucl Med Mol Imaging20103771335134420157707
   PubMed Web of Science ®Google Scholar
• NilssonSLarsenRHFossåSDFirst clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastasesClin Cancer Res200511124451445915958630
   PubMed Web of Science ®Google Scholar
• NilssonSFranzénLParkerCBone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II studyLancet Oncol20078758759417544845
   PubMed Web of Science ®Google Scholar
• SchmidtDNeumannFAntkeCPhase 1 Clinical Study on Alpha-Therapy for Non-Hodgkin Lymphoma4th Alpha-Immunotherapy SymposiumJune 28–29, 2004Dusseldorf, Germany12
   Google Scholar
• AllenBJFuture prospects for targeted alpha therapyCurr Radiopharm20114433634222202156
   PubMedGoogle Scholar
• KratochwilCGieselFLBruchertseiferFDose escalation study of peptide receptor alpha-therapy with arterially administered ²¹³Bi-DOTATOC in GEP-NET patients refractory to beta-emittersPresented at: Ann Congress European Assoc Nuclear MedicineOctober 15–19, 2011Birmingham
   Google Scholar
• RosenblatTLMcDevittMRMulfordDASequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemiaClin Cancer Res201016215303531120858843
   PubMed Web of Science ®Google Scholar
• International Atomic Energy AgencyAlpha Emitting Radionuclides and Radiopharmaceuticals for TherapyMeeting Report, International Atomic Energy AgencyJune 24–28, 2013Vienna Available from: http://www-naweb.iaea.org/napc/iachem/working_materials.htmlAccessed May 27, 2014
   Google Scholar
• WilburDSChemical and radiochemical considerations in radiolabeling with α-emitting radionuclidesCurr Radiopharm20114321424722201710
   PubMedGoogle Scholar
• Prostate Cancer FoundationResearch News: Moving the Dial to Cure; can Targeted Radiotherapy Actually Eradicate Tumors in Men with Advanced Prostate Cancer? Available from: http://www.pcf.org/site/c.leJRIROrEpH/b.8922409/k.8A41/Moving_the_Dial_to_Cure_Can_Targeted_Radiotherapy_actually_eradicate_tumors_in_men_with_advanced_prostate_cancer.htm?msource=jan14npAccessed May 27, 2014
   Google Scholar
• ParkerCNilssonSHeinrichDAlpha emitter radium-223 and survival in metastatic prostate cancerN Engl J Med2013369321322323863050
   PubMed Web of Science ®Google Scholar
• NilssonSStrangPAksnesAKA randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancerEur J Cancer201248567868622341993
   PubMed Web of Science ®Google Scholar
• ParkerCCPascoeSChodackiAA randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancerEur Urol201363218919723000088
   PubMed Web of Science ®Google Scholar
• CarrasquilloJAO’DonoghueJAPandit-TaskarNPhase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancerEur J Nucl Med Mol Imaging20134091384139323653243
   PubMed Web of Science ®Google Scholar